Functional assays, such as CCK‐8, colony formation, EdU, and transwell assays, demonstrated that NIBAN2 knockdown significantly decreased glioma cell aggressiveness (Figure 3A–C and Figure S2E), indicating that NIBAN2 plays a key role in these processes. Here, NIBAN2 is linked to central nervous system cancer.